(Q53618653)

English

A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25676423

A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia. (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25676423

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25676423

author name string

A K Burnett

1

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25676423

N Russell

2

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25676423

N Panoskaltsis

4

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25676423

A Khwaja

5

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25676423

C Hemmaway

6

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25676423

P Cahalin

7

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25676423

R E Clark

8

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25676423

D Milligan

9

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25676423

publication date

13 February 2015

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25676423

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25676423

29

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25676423

6

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25676423

1312-1319

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25676423

https://scigraph.springernature.com/pub.10.1038/leu.2015.38

0 references

The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.38

21 January 2018

Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.38

21 January 2018

European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.38

21 January 2018

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.38

21 January 2018

The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.38

21 January 2018

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.38

21 January 2018

Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.38

21 January 2018

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.38

21 January 2018

Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.38

21 January 2018

Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.38

21 January 2018

Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.38

21 January 2018

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.38

21 January 2018

Applicability of a "Pick a Winner" trial design to acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.38

21 January 2018

Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.38

21 January 2018

Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.38

21 January 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.38

21 January 2018

Age and acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.38

21 January 2018

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.38

21 January 2018

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.38

21 January 2018

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.38

21 January 2018

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.38

21 January 2018

A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25676423

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/25676423

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective antimetastatic activity of cytosine analog CS-682 in a red fluorescent protein orthotopic model of pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25676423

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly

1 reference

https://pubmed.ncbi.nlm.nih.gov/25676423

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/25676423

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/25676423

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest

1 reference

https://pubmed.ncbi.nlm.nih.gov/25676423

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/LEU.2015.38

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25676423

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25676423

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53618653&oldid=1513621283"